Kingswood Wealth Advisors LLC Has $401,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Kingswood Wealth Advisors LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 85.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,714 shares of the medical instruments supplier’s stock after purchasing an additional 789 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $401,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BDX. International Assets Investment Management LLC bought a new position in Becton, Dickinson and Company during the 4th quarter worth about $36,314,000. Americana Partners LLC grew its holdings in shares of Becton, Dickinson and Company by 17.0% in the 4th quarter. Americana Partners LLC now owns 1,052 shares of the medical instruments supplier’s stock valued at $257,000 after acquiring an additional 153 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 55.6% in the 4th quarter. Sequoia Financial Advisors LLC now owns 5,609 shares of the medical instruments supplier’s stock valued at $1,368,000 after acquiring an additional 2,005 shares in the last quarter. Impax Asset Management Group plc grew its holdings in shares of Becton, Dickinson and Company by 15.3% in the 4th quarter. Impax Asset Management Group plc now owns 919,899 shares of the medical instruments supplier’s stock valued at $223,795,000 after acquiring an additional 122,038 shares in the last quarter. Finally, Harbor Investment Advisory LLC grew its holdings in shares of Becton, Dickinson and Company by 34.3% in the 4th quarter. Harbor Investment Advisory LLC now owns 5,722 shares of the medical instruments supplier’s stock valued at $1,395,000 after acquiring an additional 1,461 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded down $2.89 during midday trading on Wednesday, reaching $232.62. The company’s stock had a trading volume of 1,104,432 shares, compared to its average volume of 1,457,544. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.97 and a current ratio of 1.85. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $284.48. The business’s 50 day moving average price is $233.22 and its two-hundred day moving average price is $236.30. The company has a market cap of $67.23 billion, a P/E ratio of 51.24, a P/E/G ratio of 2.06 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.96 earnings per share. On average, analysts forecast that Becton, Dickinson and Company will post 13.06 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $236.73, for a total transaction of $781,209.00. Following the sale, the executive vice president now owns 11,308 shares of the company’s stock, valued at $2,676,942.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total transaction of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the sale, the executive vice president now directly owns 11,308 shares in the company, valued at approximately $2,676,942.84. The disclosure for this sale can be found here. Insiders have sold 6,900 shares of company stock valued at $1,634,112 over the last three months. 0.31% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of several recent analyst reports. Barclays raised their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Citigroup cut their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective for the company. Finally, StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $279.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.